Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2012-08-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Tea contains high amounts of polyphenols with important biological activities. The green tea catechin epigallocatechin-3-gallate (EGCG) is the most potent physiologically active compound in vitro. However, little is known about its contribution to beneficial effects of tea in vivo.
In this crossover study the impact of a single dose of EGCG applied in different forms (green tea beverage, green tea extract and EGCG) on flow-mediated dilation is investigated in healthy volunteers two hours after ingestion. The amount of EGCG (200 mg) corresponds to appr. 0.5 L of green tea. The results of the study will elucidate the contribution of EGCG in cardiovascular protective effects of green tea in vivo. The outcomes will provide insights about the role of EGCG in different application forms to improvements of endothelial function in humans.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Epigallocatechin Gallate (EGCG) in Healthy, Young Adults
NCT00981292
Investigating the Effects of Green Tea on Blood Viscosity
NCT06740448
Flow Mediated Dilation in Response to Black Tea
NCT02273323
Matcha Green Tea Effects at Rest and During Moderate-intensity Exercise in Females
NCT05882942
Effects of Green Tea on Cardiometabolic Outcomes
NCT06795438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Green tea beverage
200 mg EGCG as green tea beverage.
Green tea beverage
Green tea extract
200 mg EGCG as green tea extract and same volume water as for tea beverage.
Green tea extract
Epigallocatechin-3-gallate (EGCG)
200 mg EGCG and same volume water as for tea beverage.
EGCG
Placebo (Water)
Same volume water as for all intervention arms.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Green tea beverage
Green tea extract
EGCG
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 20-50 years
* BMI \< 27 kg/m2
* Cholesterol \< 240 mg/dl
Exclusion Criteria
* Hypertension
* Conditions with impaired endothelial function
* Smoking
* Regular drug use
* Alcohol abuse
* Regular tea drinkers
20 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mario Lorenz, PhD
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mario Lorenz, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiology and Angiology, Campus Mitte, Charité University Medicine Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology and Angiology, Campus Mitte, Charité University Medicine Berlin
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Char-EGCG-FMD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.